Continuous at-home monitoring with smart device-based photoplethysmography technology could be a viable strategy for AFib screening and early detection, according to a population-level study out of China.

Men who live on their own—but not women—struggle to take warfarin as directed, according to research presented Sept. 2 at the ESC Congress in Paris.

Three-year results from the BIO-RESORT trial revealed that despite significant differences in stent backbone and polymer coating, the ultrathin sirolimus-eluting stent, very-thin everolimus-eluting stent and thin-strut zotarolimus-eluting stent remained equally safe and effective through follow-up.

Research presented this month at the ESC Congress in Paris suggests that getting a yearly influenza shot could greatly cut hypertensive patients’ risk of dying during flu season.

Complete revascularization is superior to culprit-lesion-only PCI in patients with both STEMI and multivessel disease, according to results from the COMPLETE trial, published Sept. 1 in the New England Journal of Medicine.

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

Using donor hearts from patients who died of traumatic brain injury might be a more viable option for transplant candidates than previously thought, according to an analysis published in the Journal of the American Heart Association Aug. 30.

Biomedical tech company Biobeat has received 510K clearance for its noninvasive, cuffless BP-monitoring systems.